Clinical trials: Ovarian Tumor
Platinum-resistant Ovarian Cancer
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
The purpose of this Chinese extension study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer.
- Trial name
- RAINFOL-02 (NCT07604766)
- Testing
- Rina-S, Paclitaxel, Topotecan
- Where
- 17 sites in China
- Volunteers
- 82 people
- Sponsor
- Genmab
Ovarian Cancer
Quality-of-Life Assessment in Patients With Ovarian Cancer
RATIONALE: Quality-of-life assessment in patients undergoing cancer treatment may help determine the intermediate- and long-term effects of treatment.
- Trial name
- NCT00003772
- Testing
- quality-of-life assessment
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 372 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer
Elecsys HE4 Chinese Reference Value Study
Aim of this study is to provide specimens for establishing reference values of HE4 in an apparently healthy Chinese population using the Roche Elecsys HE4 assay tested on variety of Elecsys and cobas brand immunoassay analyzers.
- Trial name
- NCT01738269
- Where
- 9 sites in China
- Volunteers
- 2,351 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Ovarian Cancer, Surgery
PROADAPT-ovary/EWOC-2
PROADAPT is a standardized geriatric intervention that is currently being co-constructed during an exploratory phase on a multi-professional and multi-disciplinary basis after a systematic analysis of published data (Figure).
- Trial name
- NCT04284969
- Testing
- PROADAPT program
- Where
- 11 sites in France
- Volunteers
- 292 people
- Sponsor
- Hospices Civils de Lyon
Polycystic Ovary Syndrome
Women With Polycystic Ovary Syndrome (PCOS)
Metabolic profile in women of different body composition with polycystic ovary syndrome.
- Trial name
- PCOS (NCT02467751)
- Where
- Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Irmandade da Santa Casa de Misericordia de Sao Paulo
Cancer, Fertility
The Experience of TYAC Offered Ovarian Tissue Cryopreservation
This study looks at the experiences of teenagers and young adults who have been offered ovarian tissue cryopreservation prior to cancer treatment as a result of their cancer and/or cancer treatment putting them at…
- Trial name
- NCT02830061
- Testing
- Interviews
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease After Standard Therapies
- Trial name
- DUAL-OV-CAR-NK (NCT07617753)
- Testing
- Dual-target CAR-NK cell product, Cyclophosphamide, supportive
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Ovarian Cancer, Primary Peritoneal Cancer
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination…
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01196559
- Testing
- Vinorelbine and Gemcitabine
- Where
- 4 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- The Catholic University of Korea
Ovarian Cancer
Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
Epithelial ovarian carcinoma (EOC) is the 5th leading cause of death among women. Long-term survival is poor for the majority of women with EOC because many present with advanced disease.
- Trial name
- NCT00239980
- Testing
- dalteparin
- Where
- 9 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Fetal Ovarian Cyst, Neonatal Ovarian Cyst
Fetal Ovarian Cysts and IOTA Terminology for Perinatal Management
Fetal ovarian cysts are common prenatal findings with a highly variable clinical course, ranging from spontaneous resolution to complications such as torsion, hemorrhage, or rupture requiring surgery.
- Trial name
- F-IOTA (NCT07587580)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Oxygen Deficiency, Acute Kidney Injury
Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
Tissue oximetry obtained from peripheral muscle measures the state of tissue oxygenation of various organs and, as already widely described in the literature, can be used to measure the state of kidney's tissue oxygenation.
- Conditions
- Oxygen Deficiency, Acute Kidney Injury, Ovarian Carcinoma
- Trial name
- NCT06475261
- Testing
- Tissue Oximetry with ForeSight
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer
Optional Sub-study to Intraoperative Imaging With ICG Registry
The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.
- Conditions
- Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
- Trial name
- NCT02651246
- Testing
- data collection
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Polycystic Ovary Syndrome, Dental Caries
Oxidative Stress in Polycystic Ovary Syndrome With Periodontal Disease and Dental Caries Lesions
This study evaluates the oxidative stress parameters in females with polycystic ovary syndrome (PCOS) and clinically healthy. Because of the fact that both oral disease included periodontitis and dental caries, and metabolic…
- Trial name
- NCT03594968
- Testing
- polycystic ovary syndrome
- Where
- Turkey (Türkiye)
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
- Conditions
- Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms
- Trial name
- NCT02837991
- Testing
- CDX-014
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celldex Therapeutics
Epithelial Ovarian Cancer
Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)
Imaging evaluation was performed every 3 months (± 7 days) from enrollment, and real-time examination was performed if new lesions were suspected.
- Trial name
- NCT07495397
- Testing
- Daphne Extract Capsules
- Where
- China
- Volunteers
- 98 people
- Sponsor
- The First Hospital of Jilin University
Advanced Solid Tumor
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated…
- Trial name
- NCT04890613
- Testing
- CX-5461
- Where
- 8 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Senhwa Biosciences, Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Epithelial Cancer
The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
The PROOV study is an open-label, monocenter, single-arm, prospective phase I/II trial with a safety lead-in, evaluating the feasibility of combining PARPi with HIPEC in stage III EOC patients.
- Conditions
- Ovarian Cancer, Epithelial Cancer, Fallopian Tube Cancer
- Trial name
- PROOV (NCT07460180)
- Testing
- Olaparib
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- The Netherlands Cancer Institute
Epithelial Ovarian Cancer
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.
- Trial name
- NCT05212779
- Testing
- Signatera testing, Altera Testing
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
This is a multicenter, open-label, non-randomized pilot study (Phase II). The aim is to obtain evidence of efficacy of niraparib and dostarlimab (TSR-042) in patients with relapsed ovarian cancer in two experimental cohorts and…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05126342
- Testing
- Niraparib, Dostarlimab
- Sponsor
- AGO Research GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.